Vancouver, British Columbia--(Newsfile Corp. - November 24, 2021) - PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) (the "Company" or "PreveCeutical"), is pleased to announce it has filed a provisional application at the Australian Patent Office on November 18, 2021, entitled "Peptides and Uses Thereof", application number 2021903722, with the aim of seeking protection for certain peptides comprising D-amino acids and their use in methods of treating brain cancer.
Compounds in these Peptides may be suitable for the treatment of cancers in which extracellular matrix metalloprotease ("MMP") or other proteinases such as urokinase-type plasminogen activator (uPa) are implicated. MMPs are known to exert effects on the extracellular microenvironment, for example, degradation of the extracellular matrix, thereby allowing cancer cell invasion.
Gliomas, which represent 40% to 45% of all intracranial tumours, are characterized by their potent ability to infiltrate surrounding normal brain tissue, making them a challenge to treat. Glioblastoma multiforme ("GBM") is the most common and fatal form of brain cancer, affecting adults between the ages of 45 and 60 years. Current treatments for GBM include chemotherapy, radiotherapy and surgery, with the survival of most patients being about one year from diagnosis.
The provisional patent application is to protect the peptides comprising D-amino acids identified in the BSV research project. These peptides have the potential, at least in part, to work as an MMP inhibitor.
PreveCeutical's Chief Executive Officer, Mr. Stephen Van Deventer, commented, "We are very pleased with the BSV Program outcomes. In addition to the provisional patent filed for the lead peptides in December 2020, PreveCeutical has now filed another patent for Peptides comprising D-amino acids. Possible treatments from the peptides identified in this patent will further our plans for cancer treatments, including management of GBM".
Although PreveCeutical believes that any such intentions, plans, estimates, beliefs, and expectations in this news release are reasonable, there can be no assurance that any such intentions, plans, beliefs, and expectations will prove to be accurate or successful.
About PreveCeutical
PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products. The Company aims to be a leader in the preventive health sciences sector.
With the completion of three of its research programs, the Company is actively working on the development, clinical trials, and commercialization of its products; and has filed a number of provisional patent applications to protect the intellectual property from its research programs.
For more information about PreveCeutical, please visit our website www.PreveCeutical.com or follow us on Twitter and Facebook.
On behalf of the Board of Directors of PreveCeutical
Stephen Van Deventer, Chairman and Chief Executive Officer
For further information, please contact:
Stephen Van Deventer: +1 604 306 9669
Or Investor Relations ir@preveceutical.com